Apogee Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, 6.76, 200.6, 790.74 ], "ebit_estimate": [ -353.46, -434.58, -526.46, -453.1, -100.09 ], "ebitda_estimate": [ -360.25, -414, -491.62, -367.1, -127 ], "net_income_estimate": [ -324.95, -404.35, -495.61, -442.36, -97.44 ], "per_share_eps_estimate": [ -4.37, -5.39, -6.33, -5.64, -1.29 ], "eps_nri_estimate": [ -4.48, -5.48, -6.49, -5.65, -1.31 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 14.93, 10.87, 8.79, 5.76, 5.14 ], "pretax_income_estimate": [ -319.48, -407.71, -495.61, -441.56, -97.05 ], "operating_cash_flow_per_share_estimate": [ -3.35, -3.73, -4.54, 0.1, -1.66 ], "roa_estimate": [ -33, -33.7, -59.8, -17.1, -22.1 ], "roe_estimate": [ -35.07, -40.15, -52.5, -22.3, -32.5 ], "gross_margin_estimate": [ null, null, null, 79, 79.97 ], "operating_cash_flow_estimate": [ -233.39, -260.09, -316.29, 6.97, -115.65 ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -16.12, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -15.31, "future_eps_nri_estimate_growth": -16.12, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -22.65, "future_ebitda_estimate_growth": -19.52, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -24.64, "future_pretax_income_estimate_growth": -24.99, "future_book_value_per_share_estimate_growth": -14.28, "future_roa_estimate_growth": -22.93, "future_roe_estimate_growth": -34.86, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -7.08 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -85.76, -89.98, -96.27, -92.65, -94.98, -97.15, -99.45 ], "ebitda_estimate": [ -87.91, -92.96, -101.4, null, null, null, null ], "net_income_estimate": [ -78.97, -83.02, -90.05, -85.96, -88.62, -91.12, -93.78 ], "per_share_eps_estimate": [ -1.05, -1.11, -1.19, -1.13, -1.17, -1.22, -1.26 ], "eps_nri_estimate": [ -1.07, -1.13, -1.22, -1.13, -1.17, -1.22, -1.26 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -79.16, -83.37, -90.97, -88.41, -91.13, -93.66, -96.33 ], "operating_cash_flow_per_share_estimate": [ -1.03, -1.03, -1.09, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ -71.76, -71.76, -75.94, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -16.12, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -15.31, "future_eps_nri_estimate_growth": -16.12, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -22.65, "future_ebitda_estimate_growth": -19.52, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -24.64, "future_pretax_income_estimate_growth": -24.99, "future_book_value_per_share_estimate_growth": -14.28, "future_roa_estimate_growth": -22.93, "future_roe_estimate_growth": -34.86, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -7.08 }